Fig. 1 · Structure

Documents & Downloads

Tiplaxtinin (PAI-039)

Cat. No. A14190 CAS 393105-53-8

PAI-1 inhbitor

Tiplaxtinin is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 of 2.7 μM.

In Stock

Publications for Tiplaxtinin (PAI-039)

1 publication citing this product

  1. Saijo A, .et al. , Cancer Lett, 2018, May 1;421:17-27 PMID: 29448000

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Tiplaxtinin (PAI-039) reduced PAI-1/uPA complex formation and promoted PAI-1 cleavage in a cell-free assay using stabilized recombinant PAI-1. The gel findings support substrate-like behavior under these conditions; they do not establish a binding affinity or IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PAI-1 2.7 μM

Tiplaxtinin (PAI-039) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Tiplaxtinin (PAI-039) from 3 published references. In vitro models include newborn rat arterial smooth muscle cells (RASMCs), in complete medium.

Tiplaxtinin (PAI-039) In Vitro Studies

In rat arterial smooth muscle cells, 24-hour tiplaxtinin treatment at 1–50 µM increased Annexin-V fluorescence relative to the zero-dose control, consistent with an apoptotic response in this model. [1]

Cell-free PAI-1/uPA complex formation and cleavage

Biochemical assay · Full-length stabilized recombinant human PAI-1 (14-1b) and human high-molecular-weight uPA in a cell-free assay. [1]

Tiplaxtinin reduced PAI-1/uPA complex bands and promoted a lower-molecular-weight PAI-1 cleavage product. This supports substrate-like behavior under the tested conditions; it is not a direct binding or potency determination.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PAI-1/uPA complex formation and PAI-1 cleavageQualitative SDS-PAGE pattern Complex bands decreased and cleaved PAI-1 appeared as tiplaxtinin increased; qualitative gel result, no numerical effect size.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 10, 20, 40 and 80 µM tiplaxtinin (Fig. 2A lane labels); 500 nmol/L FL-PAI-1 and 500 nM uPA (Section 2.11).
Exposure duration
15 min tiplaxtinin/PAI-1 preincubation, followed by 5 min with uPA at 37°C.
Method
SDS-PAGE analysis after incubation in HEPES/NaCl/Tween-20 buffer.
Vehicle
Vehicle-alone comparator; vehicle composition for this cell-free assay not specified in Section 2.11.
Co-treatment
uPA is the assay reactant, not a co-therapy.
Reported limits
Preincubation temperature, replicate count and band-density quantification are not reported for Fig. 2A. No IC50 inferred.
Methods and source locations

Compound reported in the paper: Tiplaxtinin (PAI-039); Compound label in the paper: TPX

Evidence for the named research compound in the specified preparation/model; not validation of an Adooq lot or equivalence among salts.

Experimental Procedures 2.2, 2.11; Results 3.2; Fig. 2A and caption

PAI-1/uPA complex formation and PAI-1 cleavage: Comparison with uPA-alone, FL-PAI-1-alone and zero-tiplaxtinin reaction lanes. — Fig. 2A lane labels and gel; Results 3.2; Section 2.11

Tiplaxtinin increases Annexin-V signal in rat arterial smooth muscle cells

Cell-based study · Newborn rat arterial smooth muscle cells (RASMCs), in complete medium. [1]

A 24-hour exposure increased Annexin-V fluorescence across the tested tiplaxtinin concentrations, consistent with an apoptotic response in this model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Annexin-V fluorescence after treatmentAbsolute optical-density Annexin-V staining signal Increased at 1, 5, 10 and 50 µM versus 0 µM; asterisks denote p<0.05; n=3; mean ± SEM.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 1, 5, 10 and 50 µM tiplaxtinin.
Exposure duration
24 h.
Method
Treatment of RASMCs in complete medium, followed by FITC-conjugated Annexin-V fluorescence measurement in a microplate reader.
Vehicle
DMSO vehicle; Section 2.9 states that vehicle did not induce apoptosis.
Reported limits
Final DMSO percentage and whether n=3 denotes biological or technical replication are not specified for this panel.
Methods and source locations

Compound reported in the paper: Tiplaxtinin (PAI-039); Compound label in the paper: TPX

Evidence for the named research compound in the specified preparation/model; not validation of an Adooq lot or equivalence among salts.

Experimental Procedures 2.1, 2.9 and 2.13; Results 3.2; Fig. 4B and caption

Annexin-V fluorescence after treatment: FITC–Annexin-V microplate assay; no exact bar heights digitized. — Fig. 4B graph, caption; Section 2.9

Tiplaxtinin (PAI-039) In Vivo Studies

Topical tiplaxtinin impaired closure and re-epithelialization of mouse skin wounds. Keratinocyte proliferation remained comparable to vehicle, and tissue staining showed no discernible increase in cutaneous apoptosis. This result limits generalization of favorable effects across injury models. [2]

In a mouse brain-injury model, two subcutaneous 1 mg/kg doses of tiplaxtinin, given 30 minutes and 6 hours after injury, reduced lesion volume at 24 hours versus vehicle. The treatment had no detectable lesion-volume benefit in PAI-1-deficient mice. These findings are model-specific preclinical evidence. [3]

Topical tiplaxtinin impairs cutaneous wound repair

Animal study · Adult FVB/NJ mice, 6–10 weeks old, with dorsal full-thickness skin wounds. [2]

Tiplaxtinin reduced wound closure and re-epithelialization relative to vehicle. Keratinocyte Ki-67 staining was comparable, whereas fibroblast Ki-67 staining decreased; tissue TUNEL did not show a discernible treatment-related increase in apoptosis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Wound closure and re-epithelializationHistological wound closure and epithelial tongue length Both decreased versus vehicle; mean ± SEM; n=5 in duplicate; p<0.05 (Fig. 1D–E).[2]
Ki-67-positive cutaneous cellsKi-67 immunoreactivity Keratinocyte staining comparable between groups (N.S. in Fig. 3C); fibroblast staining decreased (p<0.05 in Fig. 3D); mean ± SEM.[2]
Cutaneous cell apoptosisQualitative TUNEL staining No apoptotic keratinocytes identified; few apoptotic fibroblasts with no discernible difference between groups.[2]

Conditions shared by the study groups

Route
Topical application to each wound.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Topical tiplaxtinin
6 mg/kg as reported by the authors; 10 µL formulation applied to each wound.
Matched DMSO/PBS vehicle-treated wounds.Reduced closure and epithelial tongue length; no discernible increase in cutaneous apoptosis.[2]
Topical vehicleComparator for tiplaxtinin-treated wounds.Greater wound closure and re-epithelialization than the tiplaxtinin arm.[2]
Topical tiplaxtinin
Model: Adult FVB/NJ mice, 6–10 weeks old, with dorsal full-thickness skin wounds.
Frequency: Immediately after wounding, then daily for 4 additional consecutive days.
Treatment course: Five applications; tissue evaluated on day 5.
Vehicle: 1.25 µL DMSO in a total 10 µL PBS-based formulation.
Reported limits: Sex and unique animal count are not specified; Fig. 1 reports “n=5 in duplicate.” Nominal mg/kg designation is not converted to a systemic dose.
Topical vehicle
Model: Adult FVB/NJ mice, 6–10 weeks old, with dorsal full-thickness skin wounds.
Frequency: Same application schedule as tiplaxtinin.
Treatment course: Evaluated on day 5.
Vehicle: 1.25 µL DMSO diluted with PBS to 10 µL.
Reported limits: Four wounds were created per mouse; allocation and nesting of the reported n are not clarified in the inspected text.
Methods and source locations

Compound reported in the paper: Tiplaxtinin (PAI-039); Compound label in the paper: TPX

Evidence for the named research compound in the specified preparation/model; not validation of an Adooq lot or equivalence among salts.

Materials and Methods: In vivo wounding, Quantitation of wound closure and re-epithelialization, Immunohistochemistry, Statistical analysis; Figs. 1, 3B–D and 5A–D with captions

Wound closure and re-epithelialization: ImageJ measurement on wound sections. — Fig. 1A–E and caption; Quantitation of wound closure and re-epithelialization

Ki-67-positive cutaneous cells: Direct cell counts in three different fields as reported; not assumed to be three independent mice. — Fig. 3B–D and caption; Results “PAI-1 inhibition has no effect on keratinocyte proliferation”

Cutaneous cell apoptosis: No-terminal-transferase negative control and DNase-treated positive control; no numerical effect size reported. — Fig. 5A–D and caption; Results “Loss of PAI-1 activity does not alter wound bed cell apoptosis”

Topical tiplaxtinin · Materials and Methods: In vivo wounding, Quantitation of wound closure and re-epithelialization, Immunohistochemistry, Statistical analysis; Figs. 1, 3B–D and 5A–D with captions

Topical vehicle · Materials and Methods: In vivo wounding, Quantitation of wound closure and re-epithelialization, Immunohistochemistry, Statistical analysis; Figs. 1, 3B–D and 5A–D with captions

Tiplaxtinin reduces acute lesion expansion after experimental brain injury

Animal study · Male mice after controlled cortical impact; pharmacological lesion-response cohort and a separate PAI-1-deficient specificity-control cohort. [3]

At 24 hours, brain lesion volume was lower with tiplaxtinin than vehicle in wild-type mice. The same pharmacological comparison in PAI-1-deficient mice found no difference, supporting PAI-1 dependence within this model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Brain lesion volume 24 h after injuryLesion volume Tiplaxtinin: 23.4 mm³ (n=9); vehicle: 30.2 mm³ (n=8); p=0.004. A separate 15-min primary-lesion cohort was 14.2 mm³ (n=7).[3]
Lesion-volume response in PAI-1-deficient miceGenotype-specific pharmacological response No difference between tiplaxtinin and vehicle; n=6 per group.[3]
Intraparenchymal hemorrhage on histological screeningQualitative histological observation Neither vehicle nor tiplaxtinin animals showed histological signs of intraparenchymal bleeding.[3]

Conditions shared by the study groups

Route
Subcutaneous injection.
Frequency
Twice: 30 min and 6 h after injury.
Treatment course
Acute treatment; lesion measured at 24 h.
Vehicle
0.5% DMSO in normal saline.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tiplaxtinin, wild type
1 mg/kg per injection.
Vehicle comparator within the corresponding genotype; genotype cohorts are separate experiments.24-hour lesion volume 23.4 mm³; n=9.[3]
Vehicle, wild typeVehicle comparator within the corresponding genotype; genotype cohorts are separate experiments.24-hour lesion volume 30.2 mm³; n=8.[3]
Tiplaxtinin, PAI-1-deficient
1 mg/kg per injection.
Vehicle comparator within the corresponding genotype; genotype cohorts are separate experiments.No significant lesion-volume difference versus genotype-matched vehicle; n=6.[3]
Vehicle, PAI-1-deficientVehicle comparator within the corresponding genotype; genotype cohorts are separate experiments.Genotype-matched comparator for tiplaxtinin; n=6.[3]
Tiplaxtinin, wild type
Model: Male wild-type mice after controlled cortical impact.
Reported limits: Age and genotype-cohort allocation details are not specified in the selected description. Animals section lists C57Bl/6N and knockout-related C57Bl/6J backgrounds; no direct between-cohort strain comparison is inferred.
Vehicle, wild type
Model: Male wild-type mice after controlled cortical impact.
Reported limits: Age and genotype-cohort allocation details are not specified in the selected description. Animals section lists C57Bl/6N and knockout-related C57Bl/6J backgrounds; no direct between-cohort strain comparison is inferred.
Tiplaxtinin, PAI-1-deficient
Model: Male PAI-1-deficient mice after controlled cortical impact.
Reported limits: Age and genotype-cohort allocation details are not specified in the selected description. Animals section lists C57Bl/6N and knockout-related C57Bl/6J backgrounds; no direct between-cohort strain comparison is inferred.
Vehicle, PAI-1-deficient
Model: Male PAI-1-deficient mice after controlled cortical impact.
Reported limits: Age and genotype-cohort allocation details are not specified in the selected description. Animals section lists C57Bl/6N and knockout-related C57Bl/6J backgrounds; no direct between-cohort strain comparison is inferred.
Methods and source locations

Compound reported in the paper: Tiplaxtinin (PAI-039); Compound label in the paper: PAI-039

Evidence for the named research compound in the specified preparation/model; not validation of an Adooq lot or equivalence among salts.

Materials and Methods: Animals, Drug Preparation, Histological Evaluation, Statistics; Results “PAI-1 Inhibition Limits Secondary Lesion Expansion”; Fig. 2A–B and caption

Brain lesion volume 24 h after injury: Values quoted from Results, not estimated from graph. Figure error bars are SD; numerical SD values are not given in the selected text. One-way ANOVA with Holm–Šidák comparisons. — Fig. 2A and caption; corresponding Results paragraph

Lesion-volume response in PAI-1-deficient mice: Welch t test; no exact p value or lesion-volume decimal is supplied in the selected text. — Fig. 2B and caption; corresponding Results paragraph

Intraparenchymal hemorrhage on histological screening: Restricted to this acute study; not a systemic bleeding-risk assessment. — Results paragraph immediately before Fig. 2

Tiplaxtinin, wild type · Materials and Methods: Animals, Drug Preparation, Histological Evaluation, Statistics; Results “PAI-1 Inhibition Limits Secondary Lesion Expansion”; Fig. 2A–B and caption

Vehicle, wild type · Materials and Methods: Animals, Drug Preparation, Histological Evaluation, Statistics; Results “PAI-1 Inhibition Limits Secondary Lesion Expansion”; Fig. 2A–B and caption

Tiplaxtinin, PAI-1-deficient · Materials and Methods: Animals, Drug Preparation, Histological Evaluation, Statistics; Results “PAI-1 Inhibition Limits Secondary Lesion Expansion”; Fig. 2A–B and caption

Vehicle, PAI-1-deficient · Materials and Methods: Animals, Drug Preparation, Histological Evaluation, Statistics; Results “PAI-1 Inhibition Limits Secondary Lesion Expansion”; Fig. 2A–B and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 393105-53-8
Applications PAI-1 inhbitor
Formula C24H16F3NO4
Molecular Weight 439.3833
Synonyms PAI-039
SMILES
C1=CC=C(C=C1)CN2C=C(C3=C2C=CC(=C3)C4=CC=C(C=C4)OC(F)(F)F)C(=O)C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 62 mg/mL (141.1 mM)
Water Insoluble
Ethanol Warmed: 15 mg/mL (34.13 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
2.0% Tween 80+0.5% methylcellulose

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tiplaxtinin (PAI-039) Research References

  1. [1] Simone TM, Higgins SP, Archambeault J, et al. A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage Cellular signalling (2015). PMID: 25617690 DOI: 10.1016/j.cellsig.2015.01.009 Source material
  2. [2] Simone TM, Longmate WM, Law BK, et al. Targeted Inhibition of PAI-1 Activity Impairs Epithelial Migration and Wound Closure Following Cutaneous Injury Advances in wound care (2015). PMID: 26029482 DOI: 10.1089/wound.2014.0611 Source material
  3. [3] Griemert EV, Schwarzmaier SM, Hummel R, et al. Plasminogen activator inhibitor-1 augments damage by impairing fibrinolysis after traumatic brain injury Annals of neurology (2019). PMID: 30843275 DOI: 10.1002/ana.25458 Source material

Publications

1 publication citing this product

  1. Saijo A, .et al. , Cancer Lett, 2018, May 1;421:17-27 PMID: 29448000

Added to your cart

View Cart Checkout
Loading...